---
layout: post
title: New Drug Approvals 2011 - Pt. IX Ipilimumab (YervoyTM)
date: '2011-03-28T15:21:00.006+01:00'
author: Bissan Al-Lazikani
tags:
- 2011 New Drugs
- mAb Drugs
modified_time: '2011-08-21T14:43:09.235+01:00'
thumbnail: http://2.bp.blogspot.com/-AN-SDFoSxCw/TY3K9LvivSI/AAAAAAAAADU/YEgFhd3BIIg/s72-c/YERVOY.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-7069977927353245486
blogger_orig_url: http://chembl.blogspot.com/2011/03/new-drug-approvals-2011-pt-ix.html
---

<div class="separator" style="clear: both; text-align: center;"><span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;"></span></div><br />
<center style="text-align: center;"><b><span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; font-weight: normal; line-height: 18px;"><a href="http://2.bp.blogspot.com/-AN-SDFoSxCw/TY3K9LvivSI/AAAAAAAAADU/YEgFhd3BIIg/s1600/YERVOY.jpg" style="color: #5c71c1; text-decoration: underline;"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5588345865109683490" src="http://2.bp.blogspot.com/-AN-SDFoSxCw/TY3K9LvivSI/AAAAAAAAADU/YEgFhd3BIIg/s320/YERVOY.jpg" style="-webkit-box-shadow: rgba(0, 0, 0, 0.0976562) 1px 1px 5px; background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-color: rgb(237, 237, 237); border-bottom-style: solid; border-bottom-width: 1px; border-color: initial; border-left-color: rgb(237, 237, 237); border-left-style: solid; border-left-width: 1px; border-right-color: rgb(237, 237, 237); border-right-style: solid; border-right-width: 1px; border-top-color: rgb(237, 237, 237); border-top-style: solid; border-top-width: 1px; border-width: initial; box-shadow: rgba(0, 0, 0, 0.0976562) 1px 1px 5px; cursor: pointer; display: block; height: 168px; margin-bottom: 10px; margin-left: auto; margin-right: auto; margin-top: 0px; padding-bottom: 5px; padding-left: 5px; padding-right: 5px; padding-top: 5px; position: relative; text-align: center; width: 320px;" /></a><a href="https://www.ebi.ac.uk/chembltools/autoiconlarge/6,0,0,0,1,0,1,0,1" style="color: #2337a2; text-decoration: none;"><img alt="" border="0" src="https://www.ebi.ac.uk/chembltools/autoiconlarge/6,0,0,0,1,0,1,0,1" style="-webkit-box-shadow: rgba(0, 0, 0, 0.0976562) 1px 1px 5px; background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-color: rgb(237, 237, 237); border-bottom-style: solid; border-bottom-width: 1px; border-color: initial; border-left-color: rgb(237, 237, 237); border-left-style: solid; border-left-width: 1px; border-right-color: rgb(237, 237, 237); border-right-style: solid; border-right-width: 1px; border-top-color: rgb(237, 237, 237); border-top-style: solid; border-top-width: 1px; border-width: initial; box-shadow: rgba(0, 0, 0, 0.0976562) 1px 1px 5px; cursor: pointer; display: block; margin-bottom: 10px; margin-left: auto; margin-right: auto; margin-top: 0px; padding-bottom: 5px; padding-left: 5px; padding-right: 5px; padding-top: 5px; position: relative; text-align: center; width: 400px;" /></a></span></b></center><div><b><br />
</b></div><center style="text-align: center;"><b>ATC code:L01XC11</b></center><center style="text-align: left;"><br />
</center><span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">On 25th March 2011, the FDA approved Ipilimumab (trade name&nbsp;<a href="http://www.trademarkia.com/trademarks-search.aspx?tn=yervoy" style="color: #2337a2; text-decoration: none;"><b style="background-color: #a0ffff; color: black;">Yervoy</b></a><sup>TM</sup>, ATC code:L01XC11), a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for the treatment of unresectable or&nbsp;<a href="http://en.wikipedia.org/wiki/Metastasis" style="color: #2337a2; text-decoration: none;">metastatic</a>&nbsp;melanoma. (<a href="http://en.wikipedia.org/wiki/Melanoma" style="color: #2337a2; text-decoration: none;">Melanoma</a>;&nbsp;<a href="http://www.cancerhelp.org.uk/type/melanoma/" style="color: #2337a2; text-decoration: none;">CRUK melanoma</a>; OMIM:&nbsp;<a href="http://www.ncbi.nlm.nih.gov/omim/155600" style="color: #2337a2; text-decoration: none;">155600</a>; ICD:&nbsp;<a href="http://apps.who.int/classifications/apps/icd/icd10online/index.htm?gc43.htm+C43-C44" style="color: #2337a2; text-decoration: none;">C43</a>).</span><br />
<div style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px; text-align: left;"><br />
</div><div style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px; text-align: left;">Malignant melanoma is diagnosed in an estimated 160,000 new patients each year and, despite being less common than other skin neoplasms, it is responsible for 75% of skin cancer-related deaths. Current available treatment options for melanoma are limited to surgery, chemotherapy, radiotherapy and immunotherapy, although there are a number of targetted agents in the clinical development at the moment. Ipilimumab effect in melanoma is indirect and probably due to enabling a T-cell mediated immune response</div><div><div style="text-align: left;"><span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;"><br />
</span></div><span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">In a randomised clinical study that assessed the response of unresectable or metastatic melanoma patients to Ipilimumab, alone and in combination with investigational peptide vaccine adjuvant, gp100, the combination showed increased survival time (median survival of 10 months, compared with 6.4 months for patients receiving the vaccine alone) as well as a near doubling of the rates of survival at 12 months (46% vs 25%) and 24 months (24% vs 14%) as compared to the peptide alone.</span><br />
<span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;"><br />
</span><br />
<span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">Ipilimumab's molecular target is CTLA-4 (Uniprot:&nbsp;</span><a href="http://www.uniprot.org/uniprot/P16410" style="color: #2337a2; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px; text-decoration: none;">P16410</a><span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">;&nbsp;</span><a href="https://cansar.icr.ac.uk/index.php?autologin=guest&amp;redirect=treport&amp;redirect_value=P16410" style="color: #2337a2; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px; text-decoration: none;">canSAR</a><span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">&nbsp;; PFAM:&nbsp;</span><a href="http://pfam.sanger.ac.uk/protein/P16410" style="color: #2337a2; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px; text-decoration: none;">P16410</a><span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">), a negative regulator of T-cell activation. Ipilimumab augments T-cell activation and proliferation by binding to CTLA-4 and preventing its interaction with its ligands (CD80 and CD86). CTLA-4 is a membrane-bound, 223 amino acid long, T-cell protein. It contains an immunoglobulin V-type domain (PFAM:</span><a href="http://pfam.sanger.ac.uk/family/V-set" style="color: #2337a2; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px; text-decoration: none;">PF07686</a><span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">). The structure of CTLA-4 is determined (see</span><i style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">&nbsp;e.g.</i><span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">&nbsp;PDBe:</span><a href="http://www.rcsb.org/pdb/explore/explore.do?structureId=3OSK" style="color: #2337a2; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px; text-decoration: none;">3osk</a><span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">)</span><a href="http://4.bp.blogspot.com/-K1IXH1TtWF8/TZBHZwcuWrI/AAAAAAAAADc/swdsjflgNaQ/s1600/CTLA-4.png" style="color: #2337a2; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px; text-decoration: none;"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5589045645394467506" src="http://4.bp.blogspot.com/-K1IXH1TtWF8/TZBHZwcuWrI/AAAAAAAAADc/swdsjflgNaQ/s200/CTLA-4.png" style="-webkit-box-shadow: rgba(0, 0, 0, 0.09375) 1px 1px 5px; background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-color: rgb(237, 237, 237); border-bottom-style: solid; border-bottom-width: 1px; border-color: initial; border-left-color: rgb(237, 237, 237); border-left-style: solid; border-left-width: 1px; border-right-color: rgb(237, 237, 237); border-right-style: solid; border-right-width: 1px; border-top-color: rgb(237, 237, 237); border-top-style: solid; border-top-width: 1px; border-width: initial; box-shadow: rgba(0, 0, 0, 0.09375) 1px 1px 5px; cursor: pointer; display: block; height: 200px; margin-bottom: 10px; margin-left: auto; margin-right: auto; margin-top: 0px; padding-bottom: 5px; padding-left: 5px; padding-right: 5px; padding-top: 5px; position: relative; text-align: left; width: 123px;" /></a><span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">Ipilimumab has been issued with a Black Box warning as it can result in severe and fatal immune-mediated adverse reactions due to T-cell activation and proliferation, particularly enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.</span><br />
<span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;"><br />
</span><br />
<span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">Ipilimumab is administered intravenously, and the recommended dose is 3 mg/kg administered over 90 minutes every 3 weeks for a total of four doses. The terminal half-life (t</span><sub style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">1/2</sub><span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">) is 14.7 days (30.1%); systemic clearance (CL) is 15.3 mL/h (38.5%); and volume of distribution at steady-state (Vss) is 7.21 L (10.5%).</span><span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">&nbsp;</span><br />
<span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;"><br />
</span><br />
<span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">The full prescribing information can be found&nbsp;</span><a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf" style="color: #2337a2; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px; text-decoration: none;">here</a><span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">.&nbsp;</span><b style="background-color: #a0ffff; color: black; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">Yervoy</b><span class="Apple-style-span" style="color: #1d1d1d; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px;">™ is a product of&nbsp;</span><a href="http://www.bms.com/news/press_releases/pages/default.aspx?RSSLink=http://www.businesswire.com/news/bms/20110325005962/en&amp;t=634368972014872398" style="color: #2337a2; font-family: 'Trebuchet MS', Trebuchet, sans-serif; font-size: 13px; line-height: 18px; text-decoration: none;">Bristol-Myers Squibb</a></div><span class="Apple-style-span" style="font-family: arial, sans-serif; font-size: x-small; line-height: 15px;"></span><br />
<div style="text-align: left;"><span class="Apple-style-span" style="font-family: arial, sans-serif; font-size: x-small; line-height: 15px;"><cite style="color: #0e774a; font-style: normal;"><br />
</cite></span></div><span class="Apple-style-span" style="font-family: arial, sans-serif; font-size: x-small; line-height: 15px;"><span class="st" style="line-height: 1.24;"></span></span>